Author Affiliations: Department of Ophthalmology (Drs Fintelmann, Gilmer, Bloomer, and Jeng) and Francis I. Proctor Foundation (Drs Fintelmann, Gilmer, and Jeng), University of California, San Francisco, and Department of Ophthalmology, San Francisco General Hospital (Drs Fintelmann, Gilmer, Bloomer, and Jeng), San Francisco.
Lecythophora mutabilis is a mold that has been rarely reported as the cause of ocular infection: 1 case of endophthalmitis1 and 1 case of blebitis.2 We report a case of L mutabilis keratitis with intraocular invasion that required aggressive treatment.
A 53-year-old woman was treated for a contact lens–associated Pseudomonas aeruginosa corneal ulcer in the right eye. Fortified antibiotic eyedrops were used, but corticosteroids were not. On resolution of this infection, she developed a corneal infiltrate caused by a species of fungus that was not identifiable by a local laboratory. She began hourly treatment with voriconazole, 1%, eyedrops; because of poor clinical response, treatment with natamycin, 5%, eyedrops every 2 hours was later added. Because of the progressing infiltrate, a therapeutic deep anterior lamellar keratoplasty was performed. Postoperatively, treatment with prednisolone acetate, 1%, eyedrops every 2 hours and gatifloxacin, 0.3%, eyedrops 4 times daily was prescribed. One week postoperatively, a new infiltrate at the graft-host interface was discovered.
The patient was referred to us with visual acuity of hand motions OD. In addition to the stromal infiltrate, white clumps of presumed fungal balls were seen in the anterior chamber adherent to the cornea and iris (Figure 1). After an anterior chamber tap and injection of 0.1 mL of voriconazole (1 mg/mL), treatment with hourly voriconazole, 1%, eyedrops was started. Tap and injection of voriconazole were repeated daily for the next 2 days. No anterior chamber samples demonstrated microbiological growth. Because of the progressing infiltrate, a therapeutic penetrating keratoplasty was performed. Intraoperatively, the presumed fungal collections were peeled from the iris and the anterior chamber was irrigated with voriconazole (1 mg/mL). On histopathologic analysis, fungal filaments were seen penetrating through the cornea into the anterior chamber (Figure 2).
On the patient's first visit to us, slitlamp examination demonstrated deep infiltrates in the residual host stromal bed (following deep anterior lamellar keratoplasty) (A) and ultrasound biomicroscopy demonstrated findings consistent with a fungal mass extending from the cornea to the iris (B).
Histopathologic analysis of the posterior corneal tissue left behind at the time of deep anterior lamellar keratoplasty demonstrated fungal filaments diffusely infiltrating the host stroma and penetrating through the Descemet membrane (periodic acid–Schiff, original magnification ×10).
Postoperatively, the patient was treated with voriconazole, 200 mg orally twice daily, gatifloxacin, 0.3%, eyedrops 4 times daily, and prednisolone acetate, 1%, eyedrops 4 times daily. Six days after surgery, recurrence of the fungal infection in the host at the wound edge was noted. Tap and injection with voriconazole were performed and continued daily. Amphotericin B, 0.1 mL (100 μg/mL), was injected on the third day, and hourly amphotericin B, 0.15%, eyedrops were added owing to continued progression of the infiltrate. Five days later, the patient underwent a limbus-to-limbus penetrating keratoplasty because of worsening infection. Intraoperatively, the areas of the host cornea that clinically appeared to be infiltrated (superiorly from the 9-o’clock to 3-o’clock positions) were treated with double freeze-thaw cryotherapy before the cornea was excised, and the anterior chamber was irrigated with amphotericin B (100 μg/mL) and voriconazole (1 mg/mL).
Daily anterior chamber tap and injection of amphotericin B were continued for 4 days. Treatment with topical amphotericin B, voriconazole eyedrops, and oral voriconazole was continued for 6 weeks. At the last follow-up visit 6 months after the last procedure, although the graft had failed, there was no evidence of active infection. Cultures from the corneal tissue from the first penetrating keratoplasty had been sent to the Fungal Testing Laboratory, San Antonio, Texas, and ultimately grew L mutabilis sensitive to both amphotericin B and voriconazole by broth dilution sensitivity testing.
L mutabilis ocular infections are extremely rare and potentially very aggressive. Fortunately, our case responded to amphotericin B in contrast to the 2 reported cases in the literature.1,2 Although deep anterior lamellar keratoplasty has been reported by some investigators to be an alternative to penetrating keratoplasty in the setting of active corneal infections,3 in this instance a full-thickness graft may have been a better choice given that the infection recurred in the host bed and that fungus was found penetrating into the anterior chamber.
Correspondence: Dr Jeng, Department of Ophthalmology, University of California, San Francisco, 10 Koret Way, K-304, San Francisco, CA 94143-0730 (email@example.com).
Financial Disclosure: None reported.
Funding/Support: This work was supported in part by a grant from That Man May See and Research to Prevent Blindness to the Department of Ophthalmology, University of California, San Francisco.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.